**Central Nervous System (CNS) Agents: Sedative-Hypnotics, Non-Barbiturate**

|  |  |
| --- | --- |
| Criteria 1 | NP Criteria- Controlled Medications – Belsomra, Dayvigo, Eszopiclone, Intermezzo, Quviviq, Temazepam 7.5, Temazepam 22mg, Zolpidem ER, Zolpidem SL |
| Criteria 2 | NP Criteria- Non-Controlled Medications – Doxepin 3mg, Doxepin 6mg, Ramelteon |

|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Central Nervous System (CNS) Agents: Sedative-Hypnotics, Non-Barbiturate | | |
| **Criteria Subtitle** | Non-Preferred Products: Controlled | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred | X | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code (s) | Type of Code (GCNSeqNo, HICL, NDC) |
| BELSOMRA | 072690 | GCNSeqNo |
| BELSOMRA | 072691 | GCNSeqNo |
| BELSOMRA | 072692 | GCNSeqNo |
| BELSOMRA | 072693 | GCNSeqNo |
| DAYVIGO | 080590 | GCNSeqNo |
| DAYVIGO | 080591 | GCNSeqNo |
| ESZOPICLONE | 058482 | GCNSeqNo |
| ESZOPICLONE | 058483 | GCNSeqNo |
| ESZOPICLONE | 058484 | GCNSeqNo |
| INTERMEZZO | 068726 | GCNSeqNo |
| INTERMEZZO | 068727 | GCNSeqNo |
| QUVIVIQ | 082964 | GCNSeqNo |
| QUVIVIQ | 082965 | GCNSeqNo |
| TEMAZEPAM 7.5 and 22 mg | 019182 | GCNSeqNo |
| TEMAZEPAM 7.5 and 22 mg | 058570 | GCNSeqNo |
| ZOLPIDEM ER, SL | 059696 | GCNSeqNo |
| ZOLPIDEM ER, SL | 059697 | GCNSeqNo |
| ZOLPIDEM ER, SL | 065334 | GCNSeqNo |
| ZOLPIDEM ER, SL | 065335 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 0998 |  | Select | Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)? | New Start (initial authorization request) | 0999 |
| Continuation (re-authorization request) | 1234 |
| 2 | 0999 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 1000 |
| N | 1235 |
| 3 | 1000 |  | Select and Free Text | Has the patient had an inadequate clinical response of at least 10 days with at least two preferred drugs?  If yes, please submit the medication trials and dates. | Y | 1002 |
| N | 1001 |
| 4 | 1001 |  | Select and Free Text | Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?  If yes, please submit the medication name and reason for inability to use. | Y | 1002 |
| N | 1236 |
| 5 | 1002 |  | Select | Is the request for any of the following:  1) a nonsolid oral dosage formulation  2) a non-preferred extended release formulation  3) a non-preferred brand name that has a preferred generic product | Y | 1003 |
| N | END (Pending Manual Review) |
| 6 | 1003 |  | Select and Free Text | Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)? | Y | END (Pending Manual Review) |
| N | 1235 |
| 7 | 1234 |  | Select and Free Text | Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring? | Y | END (Pending Manual Review) |
| N | 1235 |
| 8 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |
| 9 | 1236 |  | Free Text | Please explain the reason(s) why the patient is unable to use medications not requiring prior approval. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: 180 Days

|  |  |
| --- | --- |
| **Last Approved** | 4/24/2023 |
| **Other** |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Criteria Title** | Central Nervous System (CNS) Agents: Sedative-Hypnotics, Non-Barbiturate | | |
| **Criteria Subtitle** | Non-Preferred Products: Non-Controlled | | |
| **Approval Level** | GCNSeqNo | | |
| **Products**   |  |  | | --- | --- | | Preferred |  | | Non-Preferred | X | | Brand |  | | Generic |  | | Other |  | | Drug Name | Corresponding Code (s) | Type of Code (GCNSeqNo, HICL, NDC) |
| DOXEPIN 3 mg and 6 mg | 066591 | GCNSeqNo |
| DOXEPIN 3 mg and 6 mg | 066592 | GCNSeqNo |
| RAMELTEON | 059509 | GCNSeqNo |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text** | **Choice Text** | **Next Question ID** |
| 1 | 0997 |  | Select | Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)? | New Start (initial authorization request) | 0998 |
| Continuation (re-authorization request) | 1234 |
| 2 | 0998 |  | Select | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y | 0999 |
| N | 1235 |
| 3 | 0999 |  | Select | Does the patient have a history of addiction? | Y | END (Approve x 180 days) |
| N | 1000 |
| 4 | 1000 |  | Select and Free Text | Has the patient had an inadequate clinical response of at least 10 days with at least two preferred drugs?  If yes, please submit the medication trials and dates. | Y | 1002 |
| N | 1001 |
| 5 | 1001 |  | Select and Free Text | Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?  If yes, please submit the medication name and reason for inability to use. | Y | 1002 |
| N | 1236 |
| 6 | 1002 |  | Select | Is the request for any of the following:  1) a nonsolid oral dosage formulation  2) a non-preferred extended release formulation  3) a non-preferred brand name that has a preferred generic product | Y | 1003 |
| N | END (Approve x 180 days) |
| 7 | 1003 |  | Select and Free Text | Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)? | Y | END (Approve x 180 days) |
| N | 1235 |
| 8 | 1234 |  | Select and Free Text | Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring? | Y | END (Approve x 180 days) |
| N | 1235 |
| 9 | 1235 |  | Free Text | Please provide the rationale for the medication being requested. | END (Pending Manual Review) | |
| 10 | 1236 |  | Free Text | Please explain the reason(s) why the patient is unable to use medications not requiring prior approval. | END (Pending Manual Review) | |

LENGTH OF AUTHORIZATIONS: 180 days

|  |  |
| --- | --- |
| **Last Approved** | 4/24/2023 |
| **Other** |  |